US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
